GoldenGolden
Advanced Search
Third Rock Ventures

Third Rock Ventures

Third Rock Ventures is a venture capital firm based in Boston, founded in 2007, which invests in biotechnology startups.

Third Rock Ventures is a venture capital firm headquartered in Boston, Massachusetts. The firm was established by Kevin Starr, Mark Levin, and Robert Tepper in 2007. As of July 2019, Third Rock Ventures is managing an active portfolio of 34 companies and has sold off its ownership in 57 companies. The firm specializes in funding companies at the early stage of development, in the field of biotechnology. Third Rock ventures provided venture capital to MyoKardia, a company which focuses on genetic heart diseases, that went public in 2015.

Timeline

October 31, 2016
Third Rock announces $616m Fund IV

Associated investment funds

People

Name
Role
LinkedIn

Agnieszka Czechowicz

Advisor

Alice Jacobs

Employee

Chris Varma

Employee

Craig Muir

Partner, Cheif Technology Officer

Daniel Poscover

Employee

Elizabeth Kwo, MD

Employee

Emily Duff

Employee

Hana Bauguess

Employee

Ivan Hyep

Employee

Kevin Gillis

Partner, CFO

Michelle Gonzalez

Employee

Richard Cammett

Employee

Sarah Larson

Partner, Chief Human Resources Officer

Walter Kowtoniuk

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Ambys Medicines

Cedilla Therapeutics

Celsius

Cibiem

Corvia Medical

Decibel Therapeutics

Element Science

Fulcrum Therapeutics

GBT

Goldfinch Bio

Page 1 of 3

News

Title
Author
Date
Publisher
Description
BioSpace
June 23, 2021
BioSpace
Third Rock Ventures today announced the launch of Abata Therapeutics.
Alex Keown
June 23, 2021
BioSpace
The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.
BioSpace
June 14, 2021
BioSpace
Asher Biotherapeutics today announced the formation of its Scientific Advisory Board, with the appointment of five leading scientists in the fields of immunology, oncology and protein therapeutics.
May 13, 2021
BioSpace
Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors - read this article along with other careers information, tips and advice on BioSpace
Melanie Senior
April 1, 2021
Nature Biotechnology
Private biotech firms are awash with funding, raising record-breaking sums in 2020. Melanie Senior reports.
Amirah Al Idrus
March 15, 2021
FierceBiotech
Bicara launches with $40 million in seed money from Biocon to develop a pipeline of bifunctional antibodies. That includes lead program BC101, which zeroes in on EGFR-expressing cancer cells and blocks TGFβ, a protein that normally suppresses tumor growth but can be co-opted by cancer cells to promote their growth.
Amirah Al Idrus
December 10, 2020
FierceBiotech
The condensates space is where it's at: With an $81 million financing, Faze Medicines is the third company in as many months to score venture dollars in pursuit of these targets. The capital will bankroll preclinical work in a pair of neurodegenerative diseases as well as support research in other areas like cancer, virology and immunology.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.